CN109321561B - 一种用于保护体外血液中核酸的保存剂及采血管 - Google Patents
一种用于保护体外血液中核酸的保存剂及采血管 Download PDFInfo
- Publication number
- CN109321561B CN109321561B CN201710650279.1A CN201710650279A CN109321561B CN 109321561 B CN109321561 B CN 109321561B CN 201710650279 A CN201710650279 A CN 201710650279A CN 109321561 B CN109321561 B CN 109321561B
- Authority
- CN
- China
- Prior art keywords
- blood
- preservative
- blood collection
- collection tube
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 89
- 239000008280 blood Substances 0.000 title claims abstract description 89
- 239000003755 preservative agent Substances 0.000 title claims abstract description 53
- 230000002335 preservative effect Effects 0.000 title claims abstract description 53
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 18
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 18
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 claims description 8
- 229960001083 diazolidinylurea Drugs 0.000 claims description 8
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 8
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 8
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 7
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 claims description 6
- NZKCUAOWWJCEEU-UHFFFAOYSA-N O.O.[K].[K].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O Chemical compound O.O.[K].[K].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O NZKCUAOWWJCEEU-UHFFFAOYSA-N 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 abstract description 12
- 229940127219 anticoagulant drug Drugs 0.000 abstract description 12
- 230000003204 osmotic effect Effects 0.000 abstract description 9
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 210000005259 peripheral blood Anatomy 0.000 abstract description 3
- 239000011886 peripheral blood Substances 0.000 abstract description 3
- 239000013611 chromosomal DNA Substances 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 24
- 238000001514 detection method Methods 0.000 description 15
- 210000002381 plasma Anatomy 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 5
- XVIFKRWLOQOKMV-UHFFFAOYSA-N 2-(hydroxymethylamino)acetic acid;sodium Chemical compound [Na].OCNCC(O)=O XVIFKRWLOQOKMV-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- JFROQFOCFOKDKU-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;hydron;dihydrate Chemical group O.O.[K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O JFROQFOCFOKDKU-UHFFFAOYSA-L 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- JZBRFIUYUGTUGG-UHFFFAOYSA-J tetrapotassium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].[K+].[K+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O JZBRFIUYUGTUGG-UHFFFAOYSA-J 0.000 description 3
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 238000007399 DNA isolation Methods 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- HLWRUJAIJJEZDL-UHFFFAOYSA-M sodium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC([O-])=O HLWRUJAIJJEZDL-UHFFFAOYSA-M 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000004555 blood preservation Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- -1 more preferably Substances 0.000 description 1
- QUBQYFYWUJJAAK-UHFFFAOYSA-N oxymethurea Chemical compound OCNC(=O)NCO QUBQYFYWUJJAAK-UHFFFAOYSA-N 0.000 description 1
- 229950005308 oxymethurea Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 238000009609 prenatal screening Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011232 storage material Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
Landscapes
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710650279.1A CN109321561B (zh) | 2017-08-01 | 2017-08-01 | 一种用于保护体外血液中核酸的保存剂及采血管 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710650279.1A CN109321561B (zh) | 2017-08-01 | 2017-08-01 | 一种用于保护体外血液中核酸的保存剂及采血管 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109321561A CN109321561A (zh) | 2019-02-12 |
CN109321561B true CN109321561B (zh) | 2022-03-08 |
Family
ID=65245297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710650279.1A Active CN109321561B (zh) | 2017-08-01 | 2017-08-01 | 一种用于保护体外血液中核酸的保存剂及采血管 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109321561B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110250159A (zh) * | 2019-05-28 | 2019-09-20 | 天津中科生物科技有限公司 | 一种细胞保护液及其制备方法和应用 |
CN112244025A (zh) * | 2020-11-27 | 2021-01-22 | 上海创宏生物科技有限公司 | 大分子蛋白和/或核酸用无菌处理剂及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103789202A (zh) * | 2014-01-26 | 2014-05-14 | 付士明 | 常温保存核酸的采集容器 |
CN104830831A (zh) * | 2015-05-06 | 2015-08-12 | 厦门万基生物科技有限公司 | 一种保存外周血中游离dna的保存剂 |
CN106900692A (zh) * | 2017-03-06 | 2017-06-30 | 上海迅伯生物科技有限公司 | 一种血液dna的保存剂组合物 |
-
2017
- 2017-08-01 CN CN201710650279.1A patent/CN109321561B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103789202A (zh) * | 2014-01-26 | 2014-05-14 | 付士明 | 常温保存核酸的采集容器 |
CN104830831A (zh) * | 2015-05-06 | 2015-08-12 | 厦门万基生物科技有限公司 | 一种保存外周血中游离dna的保存剂 |
CN106900692A (zh) * | 2017-03-06 | 2017-06-30 | 上海迅伯生物科技有限公司 | 一种血液dna的保存剂组合物 |
Non-Patent Citations (1)
Title |
---|
Stabilization of circulating tumor cells in blood using a collection device with a preservative reagent;Jianbing Qin等;《Cancer Cell Int.》;20140331;第14卷(第1期);1-6 * |
Also Published As
Publication number | Publication date |
---|---|
CN109321561A (zh) | 2019-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sarker et al. | Placenta-derived exosomes continuously increase in maternal circulation over the first trimester of pregnancy | |
EP1800127B1 (en) | Whole blood preparation for cytometric analysis of cell signaling pathways | |
Sigman et al. | Semen analysis and sperm function assays: what do they mean? | |
KR102010600B1 (ko) | 대사 활성 프로필을 모니터링 및 분석하는 방법 및 그의 진단 및 치료학적 용도 | |
Fosså et al. | Prediction of posttreatment spermatogenesis in patients with testicular cancer by flow cytometric sperm chromatin structure assay | |
CN109321561B (zh) | 一种用于保护体外血液中核酸的保存剂及采血管 | |
CN114134227B (zh) | 多发性骨髓瘤预后不良生物标志物及筛选方法、预后分层模型和应用 | |
Ebrahimi-Rad et al. | Adenosine deaminase 1 as a biomarker for diagnosis and monitoring of patients with acute lymphoblastic leukemia | |
Armstrong et al. | Pre-analytical handling conditions and small RNA recovery from urine for miRNA profiling | |
CN104830830A (zh) | 一种用于保护游离dna的血液抗凝剂及其应用 | |
Rohn et al. | Survival of dairy cows after surgery to correct abomasal displacement: 2. Association of clinical and laboratory parameters with survival in cows with left abomasal displacement | |
Chiam et al. | Serum outperforms plasma in small extracellular vesicle microRNA biomarker studies of adenocarcinoma of the esophagus | |
Evenson et al. | Flow cytometric evaluation of sperm from patients with testicular carcinoma | |
CN103205430A (zh) | 人类重度子痫前期发生相关的血清微小核糖核酸标志物及其应用 | |
CN115478092A (zh) | 用于预测乳腺癌免疫治疗效果的模型 | |
CN101484586A (zh) | 检测移植物抗宿主疾病易感性或移植相关死亡率的方法和试剂 | |
Lefrère et al. | Evaluation of an algorithm based on peripheral blood hematopoietic progenitor cell and CD34+ cell concentrations to optimize peripheral blood progenitor cell collection by apheresis | |
Pauly et al. | Elevated thymidine phosphorylase activity in the plasma and ascitic fluids of tumor-bearing animals | |
Avlasevich et al. | Suitability of long‐term frozen rat blood samples for the interrogation of Pig‐a gene mutation by flow cytometry | |
WO1994006290A1 (en) | Preserved, non-infectious control cells for use in the identification of a disease through blood testing | |
Padmanabhan et al. | Use of the haematopoietic progenitor cell parameter in optimizing timing of peripheral blood stem cell harvest | |
PURVIS et al. | Application of flow cytometry to studies on the human acrosome | |
US6309816B1 (en) | Methods for diagnosing cancer by measuring creatine kinase | |
Ambar et al. | Recent advances and controversies in diagnosing and treating male infertility | |
CN109694901A (zh) | 一种用于外周血样中游离dna的保存剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240407 Address after: Room 701, Unit 2, Building 8, No. 88 Kechuang 6th Street, Beijing Economic and Technological Development Zone, Daxing District, Beijing, 100176 Patentee after: ANNOROAD GENE TECHNOLOGY (BEIJING) Co.,Ltd. Country or region after: China Patentee after: BEIJING ANNOROAD MEDICAL LABORATORY Co.,Ltd. Address before: 100176 room 701, unit 2, building 8, courtyard 88, Kechuang 6th Street, Beijing Economic and Technological Development Zone, Beijing Patentee before: ANNOROAD GENE TECHNOLOGY (BEIJING) Co.,Ltd. Country or region before: China Patentee before: ZHEJIANG ANNOROAD BIO-TECHNOLOGY Co.,Ltd. Patentee before: ANNOROAD (YIWU) MEDICAL INSPECTION CO.,LTD. |